Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. It is developing a pipeline of off-the-shelf CAR T cell candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients. Its AlloCAR T product platform involves multiplex gene-engineering and gene-editing capabilities, a proprietary lymphodepletion platform, and state-of-the-art manufacturing. Key programs include cemacabtagene ansegedleucel (cema-cel) for frontline treatment in LBCL, including DLBCL, and ALLO-316 for ccRCC. Allogene products are investigational products only; their safety and efficacy have not been established and they are not approved for commercial use by the FDA.

Allogene Therapeutics is a clinical-stage biotechnology company focused on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. It is led by world-class management with significant experience in cell therapy, and its fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing. The company is developing a pipeline of off-the-shelf CAR T cell candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients. Its mission is to create and lead the next revolution in cell therapy by delivering to patients the first AlloCAR T products for blood cancers, solid tumors and autoimmune disease.

Pioneering the development of investigational allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease.

• Cemacabtagene ansegedleucel (cema-cel)

  An allogeneic CAR T product being studied as part of 1L treatment for patients with LBCL/DLBCL who are likely to relapse.

• ALLO-316

  A key program for ccRCC.

• ALLO-329

  A next-generation, off-the-shelf dual-targeted CD19/CD70 AlloCAR T product that incorporates Dagger, Allogene's proprietary technology designed to protect CAR T cells from host immune rejection.

1. 1Home - Allogeneallogene.com
2. 2About Us - Allogeneallogene.com
3. 3ALPHA3 - Allogeneallogene.com
4. 4Resolution - Allogeneallogene.com
5. 5Allogene Therapeutics (United States)wikidata.org